Vera Therapeutics (VERA) Heads Into ASN Kidney Week As Its Undervalued Narrative Faces A Test

What the ASN Kidney Week presentations mean for Vera Therapeutics stock

Vera Therapeutics (VERA) just flagged a busy ASN Kidney Week 2026, with final ORIGIN 3 data for TRUTAKNA in IgA nephropathy and fresh PIONEER basket trial readouts set for late breaking sessions.

Those scientific updates sit against a volatile share performance. The stock closed at US$30.25 on 2 October 2026, down over the past month and past 3 months, which shapes how investors might frame the upcoming data presentations.

For context, Vera Therapeutics has seen momentum fade in recent months, with the share price down 37.78% year to date and 28.74% over 3 months, even as the 3 year total shareholder return is up 175.50% and the 1 year total shareholder return is nearly flat, with a decline of 0.82%.

Spot similar high-conviction renal and immunology plays by scanning our curated list of 35 healthcare AI stocks, which combines cutting-edge pipelines with meaningful clinical catalysts.

Vera Therapeutics has already given long term holders a strong run, yet the recent slide and looming ASN data leave a sharper question: Is most of the easy upside gone, or does valuation still leave room?

Most Popular Narrative: 61% Undervalued

The most followed narrative estimates Vera Therapeutics at a fair value of $77.50 using a 7.57% discount rate, compared with the latest close at $30.25. This indicates a wide gap that ASN Kidney Week data could either reinforce or challenge.

The full two year ORIGIN 3 data set for TRUTAKNA, including a 5.0 ml per year treatment delta in eGFR slope and a 76% risk reduction on a composite kidney endpoint, supports wider physician confidence in BAFF/APRIL modulation. This can expand TRUTAKNA adoption and lift revenue and operating leverage as fixed commercial costs are spread over more treated patients.

See why 1 investors see Vera Therapeutics as 61% undervalued.

Result: Fair Value of $77.50 (UNDERVALUED)

Still, the whole Vera Therapeutics story can be knocked off course if TRUTAKNA uptake trails analyst forecasts or if investors balk at a 78.8x future P/E.

Find out about the key risks to this Vera Therapeutics narrative.

Next Steps

Mixed about Vera Therapeutics after all this, but do not sit on the fence too long and let sentiment alone drive your view when you can weigh both sides through the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Vera Therapeutics?

If Vera Therapeutics has sharpened your thinking, do not stop here. Broaden your watchlist with focused stock ideas filtered for quality, value, and resilience.

• Chase asymmetric upside by reviewing 12 elite penny stocks with strong financials that pair smaller market caps with stronger fundamentals than many investors expect.
• Hunt for pricing gaps by scanning the 29 high quality undervalued stocks that combine solid business quality with discounted market expectations.
• Prioritise capital preservation by focusing on 31 resilient stocks with low risk scores that score well on balance sheet strength and overall risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com